Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis
- 3 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 30 (2), 365-372
- https://doi.org/10.1080/14397595.2019.1586085
Abstract
Background. Although anti-cyclic citrullinated peptide antibody (anti-CCP Ab) is reported to be found in 5-20% of patients with psoriatic arthritis (PsA), its clinical significance has not been elucidated. Objective. To clarify the association of anti-CCP Ab with clinical features in PsA. Methods. Patients were enrolled who fulfilled CASPAR criteria and visited our hospital. We retrospectively compared clinical characteristics between those who were positive and negative for anti-CCP Ab and further compared changes in disease activity in the patients treated with biological DMARDs. Results. We examined 41 patients (11 females), 7 were anti-CCP Ab-positive and 34 were negative. Age (55.0 ± 15.1 years old) and frequency of lung involvements (71.4%) in the anti-CCP Ab-positive group were significantly higher than those (40.0 ± 16.0 and 0%, respectively) in the negative group (P <0.05). RF titer (749.4 ± 860.7 U/ml) and MMP-3 (604.8 ± 1060.6) in the anti-CCP Ab-positive group was significantly higher than that (3.6 ± 4.4 U/ml and 111.2 ± 77.4, respectively) in the negative group (P <0.05). Five patients were treated with TNF inhibitors (IFX: 3 and ADA: 2) in the anti-CCP Ab-positive group, while in the negative group there were 11 (IFX: 6, ADA: 4, and ETN: 1). Within 6 months of treatment, arthritis did not improve with TNF inhibitors in the anti-CCP Ab-positive group, whereas it improved significantly in the negative group. Conclusion. In patients with PsA, anti-CCP Ab might be related to lung involvements, elderly onset, RF and MMP-3 titers, and resistance to TNF inhibitor.Keywords
This publication has 28 references indexed in Scilit:
- The need for personalised medicine for rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2010
- Antibodies against cyclic citrullinated peptide in Japanese psoriatic arthritis patientsThe Journal of Dermatology, 2010
- Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritisJournal of Dermatological Science, 2009
- Assessment of anti-cyclic citrullinated peptide in psoriatic arthritisBMC Research Notes, 2009
- Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2008
- High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor inhibitors in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2007
- Low Frequency of Anticyclic Citrullinated Peptide Antibodies in Psoriatic Arthritis But Not in Cutaneous PsoriasisJCR: Journal of Clinical Rheumatology, 2006
- Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onsetAnnals Of The Rheumatic Diseases, 2006
- Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritisAnnals Of The Rheumatic Diseases, 2005
- Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2003